EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators

Jackson A Kos, Monica Langiu iD, Shane D Hellyer iD, Karen J Gregory iD

ACS Pharmacology & Translational Science · 13.12.2024 · 7 (12) · 3671-3690

DOI: 10.1021/acsptsci.4c00213 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 05.11.2024. Verfasst von Jackson A Kos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, VIC 3052, Australia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 284 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Health, Australian Government, Department of Education and Training.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabotropic glutamate receptors are a family of eight class C G protein-coupled receptors regulating higher order brain functions including cognition and motion. Metabotropic glutamate receptors have thus been heavily investigated as potential drug targets for treating neurological disorders. Drug discovery efforts directed toward metabotropic glutamate receptor subtype 5 (mGlu5) have been particularly fruitful, with a wealth of drug candidates and pharmacological tools identified. mGlu5 negative allosteric modulators (NAMs) are promising novel therapeutics for developmental, neuropsychiatric and neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, autism spectrum disorders, substance use disorders, stroke, anxiety and depression) and show promise in ameliorating adverse effects induced by other medications (e.g., L-dopa induced dyskinesia in Parkinson's Disease). However, despite preclinical success, mGlu5 NAMs are yet to reach the market due to poor safety and efficacy profiles in clinical trials. Herein, we review the physiology and signal transduction of mGlu5. We provide a comprehensive critique of therapeutic options with respect to mGlu5 inhibitors, spanning from orthosteric antagonists to NAMs. Finally, we address the challenges associated with drug development and highlight future directions to guide rational drug discovery of safe and effective novel therapeutics.

Autor:innen und Institutionen

  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, VIC 3052, Australia.
  • ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash University, Parkville, VIC 3052, Australia.

ORCID-Profile: Monica Langiu, Shane D Hellyer, Karen J Gregory

Förderung

  • Department of Health, Australian Government
  • Department of Education and Training

Zitieren

APA

Kos, J. A., Langiu, M., Hellyer, S. D., & Gregory, K. J. (2024). Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. ACS Pharmacology & Translational Science, 7(12), 3671-3690. https://doi.org/10.1021/acsptsci.4c00213

Vancouver

Kos JA, Langiu M, Hellyer SD, Gregory KJ. Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. ACS Pharmacology & Translational Science. 2024;7(12):3671-3690. doi:10.1021/acsptsci.4c00213

BibTeX
@article{Kos2024,
  author = {Kos, Jackson A and Langiu, Monica and Hellyer, Shane D and Gregory, Karen J},
  title = {Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators},
  journal = {ACS Pharmacology & Translational Science},
  year = {2024},
  volume = {7},
  number = {12},
  pages = {3671--3690},
  doi = {10.1021/acsptsci.4c00213}
}
Kostenlos starten →